371 related articles for article (PubMed ID: 15500597)
21. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA; Bickel WK; Badger GJ; Jacobs EA
Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
[TBL] [Abstract][Full Text] [Related]
24. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Haasen C; Linden M; Tiberg F
J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
[TBL] [Abstract][Full Text] [Related]
26. In-vitro and in-vivo characterization of a buprenorphine delivery system.
Kleppner SR; Patel R; McDonough J; Costantini LC
J Pharm Pharmacol; 2006 Mar; 58(3):295-302. PubMed ID: 16536895
[TBL] [Abstract][Full Text] [Related]
27. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
Simojoki K; Lillsunde P; Lintzeris N; Alho H
Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
[TBL] [Abstract][Full Text] [Related]
28. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
29. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
[TBL] [Abstract][Full Text] [Related]
30. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
31. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
33. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
34. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.
Eder H; Jagsch R; Kraigher D; Primorac A; Ebner N; Fischer G
Addiction; 2005 Aug; 100(8):1101-9. PubMed ID: 16042640
[TBL] [Abstract][Full Text] [Related]
37. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
[TBL] [Abstract][Full Text] [Related]
38. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
Jones HE; Johnson RE; Jasinski DR; Milio L
Drug Alcohol Depend; 2005 Apr; 78(1):33-8. PubMed ID: 15769555
[TBL] [Abstract][Full Text] [Related]
39. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]